RT Journal Article
SR Electronic
T1 TEMPORAL TRENDS AND TRANSMISSION DYNAMICS OF PRE-TREATMENT HIV-1 DRUG RESISTANCE WITHIN AND BETWEEN RISK GROUPS IN KENYA, 1986-2020
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.21.23287487
DO 10.1101/2023.03.21.23287487
A1 Nduva, George M.
A1 Otieno, Frederick
A1 Kimani, Joshua
A1 Sein, Yiakon
A1 Arimide, Dawit A.
A1 McKinnon, Lyle R.
A1 Cholette, Francois
A1 Lawrence, Morris K.
A1 Majiwa, Maxwell
A1 Masika, Moses
A1 Mutua, Gaudensia
A1 Anzala, Omu
A1 Graham, Susan M.
A1 Gelmon, Larry
A1 Price, Matt A.
A1 Smith, Adrian D.
A1 Bailey, Robert C.
A1 Medstrand, Patrik
A1 Sanders, Eduard J.
A1 Esbjörnsson, Joakim
A1 Hassan, Amin S.
YR 2023
UL http://medrxiv.org/content/early/2023/03/22/2023.03.21.23287487.abstract
AB Background Evidence on the distribution of pre-treatment HIV-1 drug resistance (HIVDR) by risk groups is limited in Africa. We assessed prevalence, trends, and transmission dynamics of pre-treatment HIVDR within-and-between men who have sex with men (MSM), people who inject drugs (PWID), female sex workers (FSW), heterosexuals (HET), and children infected perinatally in Kenya.Methods HIV-1 partial pol sequences from antiretroviral-naïve samples collected between 1986-2020 were used. Pre-treatment RTI, PI and INSTI mutations were assessed using the Stanford HIVDR database. Phylogenetics methods were used to determine and date transmission clusters.Results Of 3567 sequences analysed, 550 (15.4%, 95% CI: 14.2-16.6) had at least one pre-treatment HIVDR mutation, which was most prevalent amongst children (41.3%), followed by PWID (31.0%), MSM (19.9%), FSW (15.1%) and HET (13.9%). No INSTI resistance mutations were detected. Among HET, pre-treatment HIVDR increased from 6.6% in 1986-2005 to 20.2% in 2011-2015 but dropped to 6.5% in 2016-2020. Overall, 22 clusters with shared pre-treatment HIVDR mutations were identified. The largest was a K103N mutation cluster involving 16 MSM sequences sampled between 2010-2017, with an estimated tMRCA of 2005 (HPD, 2000-2008). This lineage had a growth rate=0.1/year and R0=1.1, indicating propagation over 12 years among ART-naïve MSM in Kenya.Conclusions Compared to HET, children and key populations had higher levels of pre-treatment HIVDR. Introduction of INSTIs after 2016 may have reversed the increase in pre-treatment RTI mutations in Kenya. Continued surveillance of HIVDR, with a particular focus on children and key populations, is warranted to inform treatment strategies in Kenya.Summary Compared to the heterosexual population, key populations had higher levels of pre-treatment HIV-1 drug resistance (HIVDR). Propagation of HIVDR was risk-group exclusive. Introduction of integrase inhibitors abrogated propagation of reverse transcriptase inhibitors mutations among the heterosexual, but not key populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported through the Sub-Saharan African Network for TB/HIV Research Excellence (SANTHE), a DELTAS Africa Initiative [grant #DEL-15-006]. The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS) Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africas Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Wellcome Trust [grant #107752/Z/15/Z, and #209294/Z/17/Z] and the UK government. This work was also supported in part by funding from the Swedish Research Council (grants #2016-01417, and #2020-06262) and the Swedish Society for Medical Research (grant #SA-2016). The views expressed in this publication are those of the author(s) and not necessarily those of AAS, NEPAD Agency, Wellcome Trust, IAVI, Swedish Research Council, or the UK government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Science and ethics approval were obtained from the Kenya Medical Research Institute (KEMRI) Scientific and Ethics Review Unit (SERU 3547).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesNucleotide sequence data are available from GenBank under the accession numbers OM109695-OM110282